首页> 外文期刊>Materials science & engineering >Fast dissolving moxifloxacin hydrochloride antibiotic drug from electrospun Eudragit L-100 nonwoven nanofibrous Mats
【24h】

Fast dissolving moxifloxacin hydrochloride antibiotic drug from electrospun Eudragit L-100 nonwoven nanofibrous Mats

机译:从电纺Eudragit L-100无纺布纳米纤维毡中快速溶解盐酸莫西沙星抗生素药物

获取原文
获取原文并翻译 | 示例
           

摘要

Antimicrobial electrospun nonwoven Eudragit L-100 nanofibrous mats containing Moxifloxacin hydrochloride (MOX-HCL) were fabricated for fast dissolving drug delivery systems (DDSs) associated with wound infection. The morphological characterization of nanofibers using ESEM revealed that the average diameter of non-woven nanofibrous mats ranges 200‐600 nm. The nanofiber showed cylindrical shape with crack on the surface. Differential scanning calorimetric (DSC) and Wide Angle X-ray diffraction (WAXRD) demonstrate that the drug exists in an amorphous state in the nanofibers. Nanofibrous mats were also tested for mechanical strength, contact angle, swelling assay, haemolysis and disintegration test. In vitro disintegration tests demonstrated that the dissolution of Eudragit L-100 fiber mats was within 25 s which was higher compared to the pure drug. The Eudragit nanofibers showed pH-dependent drug release profiles, with slow release at pH 1.2 and burst release (around 30 s) at pH 6.8. The in-vitro quantitative and qualitative antimicrobial assay showed that the developed Eudragit L-100 nanofibrous mats with MOX-HCL concentration of 1%, 5% and 15 wt% exhibited antibacterial activities against both gram positive (Staphylococcus aureus) and gram negative (Escherichia coli) bacteria. The in-vitro cytotoxicity assay using mouse fibroblast NIH/3T3 cells demonstrated significant biocompatibility of nanofiber mats. As per the results of biological evaluation, Eudragit L-100 nanofibrous mats with 1wt% MOX-HCL could be a suitable substrate for biomedical applications. Eudragit L-100 nanofibrous mats containing Moxifloxacin hydrochloride (MOX-HCL) showed immediate DDSs for localized drug release in the wound infection at slightly acidic or alkaline conditions where faster drug release rate is required for wound healing.
机译:制备了含有盐酸莫西沙星(MOX-HCL)的抗菌电纺非织造Eudragit L-100纳米纤维垫,用于快速溶解与伤口感染相关的药物输送系统(DDS)。使用ESEM对纳米纤维进行形态学表征表明,非织造纳米纤维毡的平均直径范围为200-600 nm。纳米纤维呈圆柱形,表面有裂纹。差示扫描量热法(DSC)和广角X射线衍射(WAXRD)证明该药物以无定形状态存在于纳米纤维中。还测试了纳米纤维垫的机械强度,接触角,溶胀试验,溶血和崩解试验。体外崩解试验表明,Eudragit L-100纤维垫的溶出度在25 s之内,比纯药物的溶出度高。 Eudragit纳米纤维表现出pH依赖性药物释放曲线,在pH≥1.2时缓慢释放,在pH 6.8时突然释放(约30 s)。体外定量和定性抗菌分析表明,已开发的MOX-HCL浓度分别为1%,5%和15 wt%的Eudragit L-100纳米纤维垫对革兰氏阳性(金黄色葡萄球菌)和革兰氏阴性(大肠埃希氏菌)均表现出抗菌活性。大肠杆菌)细菌。使用小鼠成纤维细胞NIH / 3T3细胞进行的体外细胞毒性试验证明,纳米纤维垫具有明显的生物相容性。根据生物学评估的结果,具有1wt%MOX-HCL的Eudragit L-100纳米纤维垫可能是生物医学应用的合适基材。含有莫西沙星盐酸盐(MOX-HCL)的Eudragit L-100纳米纤维垫在弱酸性或碱性条件下显示了在伤口感染中局部药物释放的立即DDS,其中伤口愈合需要更快的药物释放速率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号